ABSTRACT. Canine nasal carcinomas are often treated with radiotherapy. Presence of lysis of the cribriform plate by tumor invasion (stage 4 by modified Adams's staging system) is a well-known prognostic factor. In this study, dogs with stage 4 disease were divided into two subgroups based on the presence or absence of midline shift of the olfactory or frontal lobes of the brain (Stage 4a: without presence of midline shift. Stage 4b: with midline shift). The median survival time of dogs with midline shift was significantly shorter than that of dogs without midline shift (64 vs. 208 days). Our results indicate that the finding of a midline shift might have a prognostic significance in dogs with nasal carcinoma treated with radiotherapy.
doi: 10.1292/jvms.18-0347 falx cerebri . Further, the regional lymph node status was evaluated by performing a CT scan. Information about the dogs was obtained from medical records or telephone interviews with the owner or referring veterinarian including their breed, age, clinical symptoms, survival time, and cause of death.
All dogs had received 3D-conformal radiation therapy: 4 doses of 8-9 Gy megavoltage radiotherapy given at 7-day intervals by a 4 MV X-ray linear accelerator (PRIMUS; Toshiba Medical Systems Corp., Tochigi, Japan). Individualized treatment plans were generated with 3D treatment planning software (XiO, Elekta Japan, Tokyo, Japan). The gross tumor volume (GTV) was contoured using 2 mm slice thickness CT image sets and included contrast-enhancing mass containing discharge and the brain area where the tumor was suspected to have invaded. Planning target volume (PTV) included the region 0.3-0.5 cm outside the GTV. The prescription point of radiation dose was set at the isocenter, covering over 80% of the PTV. Wedges were used, if necessary, for a homogenous dose distribution.
Survival analysis was performed using commercial statistical software GraphPad Prism 7 (GraphPad software, La Jolla, CA, U.S.A.). Survival was defined as the interval between the date of start of radiotherapy and time of death. Dogs that remained alive at the end of the study, died from some unrelated cause or were euthanized were censored in the survival analysis. The Kaplan-Meier method was used to prepare overall survival (OS) curves, while the log-rank test was used to compare time-to-event distributions. A P-value of <0.05 was considered significant for all analyses.
Sixteen dogs were included in this study. There were 8 males (of which 3 had been castrated) and 8 females (all of which had been spayed). Their ages ranged from 7 to 17 years (median, 11.5 years). There were 2 mixed-breed dogs and the following 14 pure-breed ones: Shiba (n=4), Miniature Dachshund (n=3), Chihuahua (n=2), Welsh Corgi (n=1), Shetland Sheepdog (n=1), Maltese (n=1), Pug (n=1), and Sealyham Terrier (n=1). Tumor types included adenocarcinoma (n=13), transitional nasal carcinoma (n=1), undifferentiated carcinoma (n=1), and carcinoma (n=1). Eight dogs had tumor stage 4a and eight had stage 4b. Two dogs received chemotherapy with toceranib (Palladia ® , Zoetis, Tokyo, Japan) after radiotherapy. The characteristics of all patients are summarized in Table 1 .
Clinical symptoms observed before radiotherapy included epistaxis (n=14), dyspnea (n=7), facial deformity (n=6), neurologic abnormality (seizure, n=4; head tilt, n=1), and lymphadenopathy (n=7). Cytological or histological examination of lymph nodes was not performed.
Of the 16 dogs, 2 were alive at the end of the study. Thirteen dogs died due to tumor related or other causes and 1 dog was euthanized due to tumor progression. The MST for all dogs was 120.5 days (range, 38-476 days; Fig. 2 ), which was shorter than that reported in a previous study by Maruo et al., in which the MST of the dogs with cribriform plate destruction was 163 days after treatment with the same radiotherapy protocol (median total dose was 32 Gy) [11] . We hypothesized that the reason for this short time survival was due to a difference of severity in stage 4. Another report indicated that tumor extension into the cranium was associated with shorter survival in dogs with nasal tumors treated with radiotherapy [2] . Thus, we focused on the midline shift of the olfactory bulb or frontal lobes of the brain. The MST of dogs with stage 4a (208 days) was significantly longer than that of those with stage 4b (64 days; Fig. 3 and Table 2 ). The results allowed us to consider that the proportion of stage 4b (8 of 16 dogs) was responsible for the overall shorter MST in this study.
The known prognostic factors for nasal carcinoma include tumor type, stage, epistaxis, age, regional lymph node or pulmonary metastasis, and facial deformity [1, 7, 8, 12, 13] . However, there was no significant difference in the MST based on pre-therapy clinical symptoms (epistaxis, dyspnea, facial deformity, neurologic abnormality, and lymphadenopathy; Table 2 ). We did not evaluate for metastasis to regional lymph nodes in all cases, although there were none with pulmonary metastasis, which had been assessed by CT.
The major limitation of this study was the small sample set, which possibly reflected a statistical error. Despite these limitations, this study suggests that dogs with stage 4b disease have a short survival period (MST, 64 days). These results indicate that radiation therapy for dogs with stage 4b tumors might be able to improve their clinical symptoms, but not prolong survival time.
Further studies with a larger population are needed to validate the prognostic significance of a midline shift in cases with stage 4 nasal tumors.
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